The Food and Drug Administration (FDA) has approved Fetroja (cefiderocol; Shionogi) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative…
The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). Aztreonam is a monobactam that has activity against metallo β-lactamase…
A high dose and continuous infusion of cefoxitin has been associated with clinical success in treating febrile urinary tract infections in men caused by extended spectrum beta-lactamase–producing E coli.
The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval of cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.
Ceftazidime-avibactam was highly active against a large collection of gram-negative bacteria isolated from patients with complicated urinary tract infections.
There is no increased risk for adverse genitourinary complications without the catheter
No net benefit seen for screening, treatment of asymptomatic bacteriuria for nonpregnant adults
Risk significantly increased for current use and recent use, but not past use within 61 to 365 days
Represcription rate at 28 days only 4.1% from 2011 to 2015; slight increase seen for men over time
Renal pelvis dilatation persisting in later pregnancy or after birth tied to increased risk for later admission